Skip to content

Delcath Systems DCTH Return on equity

Return on equity at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
9.1%0.0pp
Boston Scientific logo
Boston ScientificBSX
14.8%+5.2pp
Altimmune logo
AltimmuneALT
-42.7%-8.7pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
174.1%
Wave Life Sciences logo
Wave Life SciencesWVE
-53.7%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-335.8%-377pp

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Calculated from Delcath Systems’s reported figures.

Based on trailing twelve months.

The official record: Delcath Systems’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's return on equity?
Delcath Systems (DCTH) reported return on equity of 1.9% in Q3 2025.
How has Delcath Systems's return on equity changed year-over-year?
Delcath Systems's return on equity increased by 100.9% year-over-year, from -205% to 1.9%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.